In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $60.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ritu Baral has given her Buy rating due to a combination of factors surrounding Vera Therapeutics’ strategic positioning and financial health. The company is advancing its Phase 3 ORIGIN3 trial, which is fully enrolled and aims to evaluate the efficacy of atacicept for treating IgA nephropathy (IgAN). The trial’s primary endpoint is expected to yield results by June, with a Biologics License Application (BLA) submission planned for the second half of 2025 and potential U.S. approval in 2026. This timeline suggests a promising path forward for Vera Therapeutics.
Additionally, Vera Therapeutics is financially well-positioned, with $598.8 million in cash at the end of the first quarter of 2025, providing sufficient operational runway through the anticipated approval and launch of atacicept. The company’s focus on a concentrated specialty market, targeting approximately 8,000 to 10,000 nephrologists in the U.S., aligns with its strategic launch plans. These factors collectively contribute to Ritu Baral’s positive outlook and Buy rating for Vera Therapeutics.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.